These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 37713144)

  • 1. The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization.
    Feferkorn I; Santos-Ribeiro S; Ubaldi FM; Velasco JG; Ata B; Blockeel C; Conforti A; Esteves SC; Fatemi HM; Gianaroli L; Grynberg M; Humaidan P; Lainas GT; La Marca A; Craig LB; Lathi R; Norman RJ; Orvieto R; Paulson R; Pellicer A; Polyzos NP; Roque M; Sunkara SK; Tan SL; Urman B; Venetis C; Weissman A; Yarali H; Dahan MH
    J Assist Reprod Genet; 2023 Nov; 40(11):2681-2695. PubMed ID: 37713144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization.
    Feferkorn I; Ata B; Esteves SC; La Marca A; Paulson R; Blockeel C; Conforti A; Fatemi HM; Humaidan P; Lainas GT; Mol BW; Norman RJ; Orvieto R; Polyzos NP; Santos-Ribeiro S; Sunkara SK; Tan SL; Ubaldi FM; Urman B; Velasco JG; Weissman A; Yarali H; Dahan MH
    J Assist Reprod Genet; 2023 May; 40(5):1071-1081. PubMed ID: 36933094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology.
    Youssef MA; Van der Veen F; Al-Inany HG; Mochtar MH; Griesinger G; Nagi Mohesen M; Aboulfoutouh I; van Wely M
    Cochrane Database Syst Rev; 2014 Oct; 2014(10):CD008046. PubMed ID: 25358904
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low dose human chorionic gonadotropin administration at the time of gonadotropin releasing-hormone agonist trigger versus 35 h later in women at high risk of developing ovarian hyperstimulation syndrome - a prospective randomized double-blind clinical trial.
    Engmann LL; Maslow BS; Kaye LA; Griffin DW; DiLuigi AJ; Schmidt DW; Grow DR; Nulsen JC; Benadiva CA
    J Ovarian Res; 2019 Jan; 12(1):8. PubMed ID: 30684970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
    Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
    Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising Follicular Development, Pituitary Suppression, Triggering and Luteal Phase Support During Assisted Reproductive Technology: A Delphi Consensus.
    Orvieto R; Venetis CA; Fatemi HM; D'Hooghe T; Fischer R; Koloda Y; Horton M; Grynberg M; Longobardi S; Esteves SC; Sunkara SK; Li Y; Alviggi C
    Front Endocrinol (Lausanne); 2021; 12():675670. PubMed ID: 34040586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of severe ovarian hyperstimulation syndrome in GnRH antagonist versus GnRH agonist protocol: RCT including 1050 first IVF/ICSI cycles.
    Toftager M; Bogstad J; Bryndorf T; Løssl K; Roskær J; Holland T; Prætorius L; Zedeler A; Nilas L; Pinborg A
    Hum Reprod; 2016 Jun; 31(6):1253-64. PubMed ID: 27060174
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized versus standard FSH dosing in women starting IVF/ICSI: an RCT. Part 2: The predicted hyper responder.
    Oudshoorn SC; van Tilborg TC; Eijkemans MJC; Oosterhuis GJE; Friederich J; van Hooff MHA; van Santbrink EJP; Brinkhuis EA; Smeenk JMJ; Kwee J; de Koning CH; Groen H; Lambalk CB; Mol BWJ; Broekmans FJM; Torrance HL;
    Hum Reprod; 2017 Dec; 32(12):2506-2514. PubMed ID: 29121269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovulation triggering with hCG alone, GnRH agonist alone or in combination? A randomized controlled trial in advanced-age women undergoing IVF/ICSI cycles.
    Zhou C; Yang X; Wang Y; Xi J; Pan H; Wang M; Zhou Y; Xiao Y
    Hum Reprod; 2022 Jul; 37(8):1795-1805. PubMed ID: 35595223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
    Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
    Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
    Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
    Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GnRH agonist versus HCG triggering in different IVF/ICSI cycles of same patients: a retrospective study.
    Yılmaz N; Ceran MU; Ugurlu EN; Gülerman HC; Engin Ustun Y
    J Obstet Gynaecol; 2020 Aug; 40(6):837-842. PubMed ID: 31791167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reproductive Outcome After GnRH Agonist Triggering With Co-Administration of 1500 IU hCG on the Day of Oocyte Retrieval in High Responders: A Long-Term Retrospective Cohort Study.
    Abdulkhalikova D; Bokal EV; Stimpfel M; Ciglar P; Korosec S
    Front Endocrinol (Lausanne); 2022; 13():826411. PubMed ID: 35464066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; Aboulfoutouh I; Khattab SM; van Wely M
    Cochrane Database Syst Rev; 2011 Jan; (1):CD008046. PubMed ID: 21249699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist assisted reproductive technology cycles.
    Youssef MA; Van der Veen F; Al-Inany HG; Griesinger G; Mochtar MH; van Wely M
    Cochrane Database Syst Rev; 2010 Nov; (11):CD008046. PubMed ID: 21069701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rescue in vitro fertilization using a GnRH antagonist in hyper-responders from gonadotropin intrauterine insemination (IUI) cycles.
    Balayla J; Granger L; St-Michel P; Villeneuve M; Fontaine JY; Desrosiers P; Dahdouh EM
    J Assist Reprod Genet; 2013 Jun; 30(6):773-8. PubMed ID: 23715874
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A simplified universal approach to COH protocol for IVF: ultrashort flare GnRH-agonist/GnRH-antagonist protocol with tailored mode and timing of final follicular maturation.
    Orvieto R
    J Ovarian Res; 2015 Nov; 8():69. PubMed ID: 26536862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral medications including clomiphene citrate or aromatase inhibitors with gonadotropins for controlled ovarian stimulation in women undergoing in vitro fertilisation.
    Kamath MS; Maheshwari A; Bhattacharya S; Lor KY; Gibreel A
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008528. PubMed ID: 29096046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GnRH antagonist versus long agonist protocols in IVF: a systematic review and meta-analysis accounting for patient type.
    Lambalk CB; Banga FR; Huirne JA; Toftager M; Pinborg A; Homburg R; van der Veen F; van Wely M
    Hum Reprod Update; 2017 Sep; 23(5):560-579. PubMed ID: 28903472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.